ABOUT US
About us
Greetings
History
HLB CI
Contact Us
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
CAR-T Therapeutics
Targeted Anti-Cancer Drugs
Anticancer immunotherapy
Healthcare
ESG
EHS
Management
http://www.hlbkorea.com/en/
친환경 제품 및 서비스
Social
contribution
Talent
Management
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance structure
주주
이사회
정관
기타
Initiative
ESG report
IR
Stock Index
Stock Info
Official Notice
PR
Notice
Press
Library
CAREERS
Eng
Korean
English
Best-in-class
anticancer
drug
HLB develops the ‘Rivoceranib’, the Best-in-class
targeted therapy for unmet medical needs in cancer.
Leader of Global
Pharma
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
IR Letter
About the Progress of the...
∙ On February 26, HLB signed a binding term sheet with Adenchen...
Apealea completes Pre-NDA...
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovar...
Press Release
HLB Life Sciences Secures...
HLB Life Sciences announced that it has secured exclusive distrib...
HLB Global acquires Barab...
HLB Global said it has acquired 355,000 shares of Barabio, a deve...
Report
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC)...
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood ves...